Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation

Transplantation

Volumn 82, Issue 3, 2006, Pages 375-381

  Taylor, Anna L ^a   Bowles, Kristian M ^a   Callaghan, Christopher J ^a   Wimperis, Jenny Z ^b   Grant, John W ^c   Marcus, Robert E ^a   Bradley, J Andrew ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anthracycline based chemotherapy; Complete remission; Histological classification; Posttransplant lymphoproliferative disorder

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; BLEOMYCIN; CALCINEURIN INHIBITOR; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GRAFT FAILURE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; NEUTROPENIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; BIOPSY; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747135907     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000228906.31675.fb     Document Type: Article

References (42)

1. Feng S, Buell JF, Chari RS, et al. Tumors and transplantation: The 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003; 3(12): 1481.
2. Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10(3): 136.
3. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13(4): 961.
4. Gottschalk S, Rooney CM, Heslop HE. Post-Transplant Lymphoproliferative Disorders. Annu Rev Med 2004.
5. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97(1): 14.
6. Paranjothi S, Yusen RD, Kraus MD, et al. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20(10): 1054.
7. Malouf MA, Chhajed PN, Hopkins P, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21(5): 547.
8. Peraira JR, Segovia J, Fuertes B, et al. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders. Transplant Proc 2003; 35(5): 2009.
9. Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 22(5): 505.
10. Libertiny G, Watson CJ, Gray DW, et al. Rising incidence of posttransplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88(10): 1330.
11. Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005; 80(2): 193.
12. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4(2): 222.
13. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56(1): 155.
14. Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87(1): 67.
15. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19(3): 772.
16. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17 Suppl 4: 31.
17. Allen U, Hebert D, Moore D, et al. Epstein-Barr virus-related posttransplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant 2001; 5(3): 198.
18. Marcus R. Current treatment options in aggressive lymphoma. Leuk Lymphoma 2003; 44 Suppl 4: S15.
19. Cullen MH, Stuart NS, Woodroffe C, et al. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group. J Clin Oncol 1994; 12(4): 779.
20. Bessell EM, Graus F, Punt JA, et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996; 14(3): 945.
21. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31(11): 1860.
22. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12): 3835.
23. Jaffe E, Harris NL, Stein H, Vardiman JW. WHO classification of Tumours. Pathology and genetics of Tumours of Haemopoetic and Lymphoid tissues. Lyon: IARC Press, 2001.
24. Linch DC, Smith P, Hancock BW, et al. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11 Suppl 1: 87.
25. DeVita VT Jr, Canellos GP, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; 1(7901): 248.
26. Mainwaring PN, Cunningham D, Gregory W, et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001; 97(10): 2991.
27. Hodson DJ, Bowles KM, Cooke LJ, et al. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases. Clin Oncol (R Coll Radiol) 2005; 17(3): 185.
28. Hancock BW, Gregory WM, Cullen MH, et al. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer 2001; 84(10): 1293.
29. Guideline on the use of Colony Stimulating Factors in Haematological Malignancies. British Committee for Standards in Haematology. Br J Haematol 2003; 123(1): 22.
30. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92(9): 3137.
31. Greiner T, Armitage JO, Gross TG. Atypical Lymphoproliferative Diseases. Hematology (Am Soc Hematol Educ Program) 2000; 133-146.
32. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29.
33. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68(12): 1851.
34. Lester JF, Dojcinov SD, Attanoos RL, et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 2003; 123(3): 463.
35. Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9(10 Pt 2): 3945S.
36. Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999; 67(7): 990.
37. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003; 17(3): 143.
38. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235.
39. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (RCHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101(11): 4279.
40. Oertel SH, Verschuuren E, Reinke P, et al. Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). Am J Transplant 2005; 5(12): 2901.
41. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002; 118(3): 728.
42. Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86(6): 618.